AR125906A2 - Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cáncer - Google Patents
Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cáncerInfo
- Publication number
- AR125906A2 AR125906A2 ARP220101320A ARP220101320A AR125906A2 AR 125906 A2 AR125906 A2 AR 125906A2 AR P220101320 A ARP220101320 A AR P220101320A AR P220101320 A ARP220101320 A AR P220101320A AR 125906 A2 AR125906 A2 AR 125906A2
- Authority
- AR
- Argentina
- Prior art keywords
- dsm
- combination
- antibody
- cancer
- agent
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 102000002029 Claudin Human genes 0.000 title 1
- 108050009302 Claudin Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 7
- 229940002612 prodrug Drugs 0.000 abstract 7
- 239000000651 prodrug Substances 0.000 abstract 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 229960002949 fluorouracil Drugs 0.000 abstract 6
- 229940123237 Taxane Drugs 0.000 abstract 4
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 4
- 229960004316 cisplatin Drugs 0.000 abstract 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 4
- 229960001756 oxaliplatin Drugs 0.000 abstract 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 3
- 239000002269 analeptic agent Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 abstract 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract 1
- 150000004663 bisphosphonates Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229960001904 epirubicin Drugs 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000010175 gallbladder cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 239000002777 nucleoside Chemical class 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Terapia combinada para tratar y/o prevenir de forma eficaz enfermedades asociadas con células que expresan CLDN18.2, incluidas enfermedades cancerosas tales como el cáncer gástrico, el cáncer esofágico, el cáncer pancreático, el cáncer de pulmón, el cáncer ovárico, el cáncer de colon, el cáncer hepático, el cáncer de cabeza y cuello y el cáncer de la vesícula biliar, y metástasis de los mismos. Reivindicación 1: Un método para tratar o prevenir una enfermedad cancerosa caracterizado porque comprende administrar a un paciente un anticuerpo que tiene la capacidad de unirse a CLDN18.2 en combinación con un agente que estabiliza o que aumenta la expresión de CLDN18.2. Reivindicación 4: El método de cualquiera de las reivindicaciones 1 a 3, caracterizado porque el agente que estabiliza o que aumenta la expresión de CLDN18.2 comprende un agente que se selecciona del grupo que consiste en antraciclinas, compuestos de platino, análogos de nucleósido, taxanos, y análogos de camptotecina, o prodrogas de los mismos, y combinaciones de los mismos. Reivindicación 5: El método de cualquiera de las reivindicaciones 1 a 4, caracterizado porque el agente que estabiliza o que aumenta la expresión de CLDN18.2 comprende un agente que se selecciona del grupo que consiste en epirubicina, oxaliplatino, cisplatino, 5-fluorouracilo o prodrogas de los mismos, docetaxel, irinotecan, y combinaciones de los mismos. Reivindicación 6: El método de cualquiera de las reivindicaciones 1 a 5, caracterizado porque el agente que estabiliza o que aumenta la expresión de CLDN18.2 comprende una combinación de oxaliplatino y 5-fluorouracilo o prodrogas de los mismos, una combinación de cisplatino y 5-fluorouracilo o prodrogas de los mismos, una combinación de al menos uno de antraciclina y oxaliplatino, una combinación de al menos uno de antraciclina y cisplatino, una combinación de al menos uno de antraciclina y 5-fluorouracilo o prodrogas de los mismos, una combinación de al menos uno de taxano y oxaliplatino, una combinación de al menos uno de taxano y cisplatino, una combinación de al menos uno de taxano y 5-fluorouracilo o prodrogas de los mismos, o una combinación de al menos uno de análogo de camptotecina y 5-fluorouracilo o prodrogas de los mismos. Reivindicación 17: El método de cualquiera de las reivindicaciones 1 a 16, caracterizado porque además comprende administrar un agente estimulante de células T gd. Reivindicación 19: El método de la reivindicación 17 o 18, caracterizado porque el agente estimulante de células T gd es un bisfosfonato. Reivindicación 25: El método de cualquiera de las reivindicaciones 1 a 24, caracterizado porque el anticuerpo que tiene la capacidad de unirse a CLDN18.2 es un anticuerpo que se selecciona del grupo que consiste en (i) un anticuerpo producido por y/o que se puede obtener de un clon depositado bajo el número de acceso DSM ACC2737, DSM ACC2738, DSM ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM ACC2745, DSM ACC2746, DSM ACC2747, DSM ACC2748, DSM ACC2808, DSM ACC2809, o DSM ACC2810, (ii) un anticuerpo que es una forma quimerizada o humanizada del anticuerpo bajo (i), (iii) un anticuerpo que tiene la especificidad del anticuerpo bajo (i) y (iv) un anticuerpo que comprende la porción de unión a antígeno o el sitio de unión a antígeno, en particular la región variable, del anticuerpo bajo (i) y preferentemente que tiene la especificidad del anticuerpo bajo (i).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/002210 WO2013174403A1 (en) | 2012-05-23 | 2012-05-23 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125906A2 true AR125906A2 (es) | 2023-08-23 |
Family
ID=48483023
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101784 AR091130A1 (es) | 2012-05-23 | 2013-05-22 | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cancer |
ARP220101320A AR125906A2 (es) | 2012-05-23 | 2022-05-17 | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cáncer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101784 AR091130A1 (es) | 2012-05-23 | 2013-05-22 | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cancer |
Country Status (26)
Country | Link |
---|---|
US (2) | US20150132253A1 (es) |
JP (2) | JP6203831B2 (es) |
KR (3) | KR102625189B1 (es) |
CN (2) | CN104379166B (es) |
AR (2) | AR091130A1 (es) |
AU (2) | AU2013265638B2 (es) |
BR (1) | BR112014028948B8 (es) |
CA (1) | CA2874032A1 (es) |
DK (2) | DK2852408T3 (es) |
ES (3) | ES2637416T3 (es) |
FI (1) | FI3791896T3 (es) |
HK (1) | HK1208152A1 (es) |
HR (2) | HRP20240169T1 (es) |
HU (2) | HUE036000T2 (es) |
IL (2) | IL235607A0 (es) |
LT (3) | LT3791896T (es) |
MX (5) | MX2014014216A (es) |
NZ (2) | NZ701585A (es) |
PL (1) | PL3791896T3 (es) |
PT (3) | PT2852408T (es) |
RS (2) | RS65179B1 (es) |
RU (1) | RU2665321C2 (es) |
SG (2) | SG10201609772PA (es) |
SI (2) | SI3254695T1 (es) |
UA (1) | UA118013C2 (es) |
WO (2) | WO2013174403A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
RU2678127C2 (ru) | 2012-11-13 | 2019-01-23 | Бионтех Аг | Агенты для лечения экспрессирующих клаудин раковых заболеваний |
WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
CN106460054A (zh) * | 2014-03-21 | 2017-02-22 | 新加坡科技研究局 | 癌症中的融合基因 |
WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
WO2018040537A1 (zh) * | 2016-08-31 | 2018-03-08 | 南京凯地生物科技有限公司 | 人pd-1基因敲除的cldn18.2 特异性嵌合抗原受体t细胞的制备方法以及应用 |
US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
US10150801B1 (en) | 2017-12-27 | 2018-12-11 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
EP3732190A1 (en) * | 2017-12-27 | 2020-11-04 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2019173420A1 (en) | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
EP3794037A4 (en) | 2018-05-18 | 2022-03-02 | Lanova Medicines Limited Company | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF |
WO2020038404A1 (zh) * | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
EP3858384A4 (en) * | 2018-09-30 | 2022-07-06 | CRAGE medical Co., Limited | COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS |
WO2020097306A1 (en) * | 2018-11-08 | 2020-05-14 | Incysus Therapeutics, Inc. | Compositions and methods for treating cancer |
CN113166246A (zh) * | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
JP2022515487A (ja) * | 2018-12-28 | 2022-02-18 | ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド | クローディン18.2結合部分およびその利用 |
TW202102546A (zh) * | 2019-04-01 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 密蛋白抗體及其應用 |
CA3137160A1 (en) * | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
KR20220012262A (ko) * | 2019-05-24 | 2022-02-03 | 산유 바이오파마슈티컬스 씨오., 엘티디. | 신형 cldn18.2 결합분자 |
CA3147122A1 (en) * | 2019-07-12 | 2021-01-21 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Cldn18.2 antibody and use thereof |
US10675332B1 (en) | 2019-08-26 | 2020-06-09 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US20240043527A1 (en) | 2020-03-30 | 2024-02-08 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2023025147A1 (zh) * | 2021-08-23 | 2023-03-02 | 南通壹宸生物医药科技有限公司 | 抗原表位修饰 |
CN114907482B (zh) * | 2021-09-03 | 2023-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
US7217703B2 (en) * | 2004-04-16 | 2007-05-15 | Emisphere Technologies, Inc. | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
US8609410B2 (en) * | 2005-09-08 | 2013-12-17 | Medinet Co., Ltd. | Method for activation treatment of antigen-presenting cell |
EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
WO2008152822A1 (ja) * | 2007-06-15 | 2008-12-18 | Medinet Co., Ltd. | 医薬 |
JP5596559B2 (ja) * | 2008-01-28 | 2014-09-24 | メディミューン リミテッド | 安定化アンジオポエチン2抗体とその用途 |
CA2731632A1 (en) * | 2008-07-25 | 2010-01-28 | Merck Patent Gmbh | Method of determination of receptor binding saturation effected by monoclonal antibodies |
WO2010141093A2 (en) * | 2009-06-04 | 2010-12-09 | The University Of Maryland, Baltimore | Co-signaling methods for treating cancers |
WO2011090005A1 (ja) * | 2010-01-19 | 2011-07-28 | 協和発酵キリン株式会社 | 大腸癌の治療用医薬および治療方法 |
-
2012
- 2012-05-23 WO PCT/EP2012/002210 patent/WO2013174403A1/en active Application Filing
-
2013
- 2013-05-21 DK DK13724523.9T patent/DK2852408T3/en active
- 2013-05-21 PT PT137245239T patent/PT2852408T/pt unknown
- 2013-05-21 BR BR112014028948A patent/BR112014028948B8/pt active IP Right Grant
- 2013-05-21 RU RU2014152115A patent/RU2665321C2/ru active
- 2013-05-21 WO PCT/EP2013/001504 patent/WO2013174510A1/en active Application Filing
- 2013-05-21 LT LTEP20194625.8T patent/LT3791896T/lt unknown
- 2013-05-21 MX MX2014014216A patent/MX2014014216A/es active IP Right Grant
- 2013-05-21 PT PT171711690T patent/PT3254695T/pt unknown
- 2013-05-21 CN CN201380026482.1A patent/CN104379166B/zh active Active
- 2013-05-21 LT LTEP17171169.0T patent/LT3254695T/lt unknown
- 2013-05-21 US US14/401,899 patent/US20150132253A1/en not_active Abandoned
- 2013-05-21 ES ES13724523.9T patent/ES2637416T3/es active Active
- 2013-05-21 DK DK20194625.8T patent/DK3791896T3/da active
- 2013-05-21 ES ES20194625T patent/ES2971318T3/es active Active
- 2013-05-21 KR KR1020217006323A patent/KR102625189B1/ko active IP Right Grant
- 2013-05-21 NZ NZ701585A patent/NZ701585A/en not_active IP Right Cessation
- 2013-05-21 SG SG10201609772PA patent/SG10201609772PA/en unknown
- 2013-05-21 SI SI201331818T patent/SI3254695T1/sl unknown
- 2013-05-21 PT PT201946258T patent/PT3791896T/pt unknown
- 2013-05-21 LT LTEP13724523.9T patent/LT2852408T/lt unknown
- 2013-05-21 HU HUE13724523A patent/HUE036000T2/hu unknown
- 2013-05-21 SG SG11201406977TA patent/SG11201406977TA/en unknown
- 2013-05-21 ES ES17171169T patent/ES2835073T3/es active Active
- 2013-05-21 HU HUE17171169A patent/HUE054214T2/hu unknown
- 2013-05-21 PL PL20194625.8T patent/PL3791896T3/pl unknown
- 2013-05-21 SI SI201332076T patent/SI3791896T1/sl unknown
- 2013-05-21 UA UAA201413810A patent/UA118013C2/uk unknown
- 2013-05-21 AU AU2013265638A patent/AU2013265638B2/en active Active
- 2013-05-21 CA CA2874032A patent/CA2874032A1/en active Pending
- 2013-05-21 RS RS20240147A patent/RS65179B1/sr unknown
- 2013-05-21 CN CN201811066117.4A patent/CN109172820B/zh active Active
- 2013-05-21 FI FIEP20194625.8T patent/FI3791896T3/fi active
- 2013-05-21 NZ NZ725347A patent/NZ725347A/en unknown
- 2013-05-21 KR KR1020147036040A patent/KR102233344B1/ko active IP Right Grant
- 2013-05-21 KR KR1020247001045A patent/KR20240010757A/ko not_active Application Discontinuation
- 2013-05-21 JP JP2015513044A patent/JP6203831B2/ja active Active
- 2013-05-21 RS RS20201449A patent/RS61127B1/sr unknown
- 2013-05-21 HR HRP20240169TT patent/HRP20240169T1/hr unknown
- 2013-05-22 AR ARP130101784 patent/AR091130A1/es not_active Application Discontinuation
-
2014
- 2014-11-10 IL IL235607A patent/IL235607A0/en active IP Right Grant
- 2014-11-21 MX MX2020011780A patent/MX2020011780A/es unknown
- 2014-11-21 MX MX2020011771A patent/MX2020011771A/es unknown
- 2014-11-21 MX MX2020011782A patent/MX2020011782A/es unknown
- 2014-11-21 MX MX2019013723A patent/MX2019013723A/es unknown
-
2015
- 2015-09-07 HK HK15108682.9A patent/HK1208152A1/xx unknown
-
2017
- 2017-08-30 JP JP2017165303A patent/JP6490764B2/ja active Active
-
2018
- 2018-02-27 AU AU2018201391A patent/AU2018201391B2/en active Active
- 2018-03-01 US US15/909,577 patent/US20180258180A1/en not_active Abandoned
-
2020
- 2020-11-23 HR HRP20201859TT patent/HRP20201859T1/hr unknown
- 2020-12-09 IL IL279330A patent/IL279330A/en unknown
-
2022
- 2022-05-17 AR ARP220101320A patent/AR125906A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR125906A2 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cáncer | |
AR091131A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cancer | |
AR094849A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer | |
ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
NI201400024A (es) | Agentes de ligación al factor de crecimiento endotelial vascular/ligando 4 similar a delta ( vegf/dll4) y usos de los mismos. | |
SG10201906075VA (en) | Methods of treating cancer | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
EA201500019A1 (ru) | Способ лечения gd2-положительного рака | |
MX2017006382A (es) | Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. | |
EA201492148A1 (ru) | Способ лечения немелкоклеточного рака легких | |
AR080244A1 (es) | Terapia anti-angiogenesis para el tratamiento del cancer ovarico | |
MX367403B (es) | Diesteres de fosfonato nucleosido aciclico. | |
WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
NZ703786A (en) | Fgfr1 extracellular domain combination therapies | |
ZA202001568B (en) | Methods and compositions for treating chronic lung diseases | |
HRP20221319T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
RU2014120179A (ru) | Терапевтическая комбинация для лечения рака | |
EA201490231A1 (ru) | Позитивные аллостерические модуляторы никотинового рецептора ацетилхолина | |
GR1008614B (el) | 3,3-διαφαινυλ-ν-(φαινυλαιθυλ)προπαν-1-αμινη: ως νεος και επιλεκτικος προσδετης των σιγμα-1 υποδοχεων, με αντι-απο πτωτικες (κυτταρο-προστατευτικες) ιδιοτητες και με πρωτοτυπη αντικαρκινικη δραση | |
WO2012075210A3 (en) | Method for treating refractory cancer | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
MX2017013669A (es) | Composiciones para el tramiento del cancer. |